Glycostigmin (Glycopyrronium Bromide, Neostigmine Methylsulfate)

Glycostigmin is employed in hospital environments where modulation of neuromuscular function is required. It may be considered in the following situations:

• Reversal of non‑depolarizing neuromuscular blockade after surgery.
• Management of residual muscle weakness in the post‑anesthesia care unit.
• Adjunct therapy during diagnostic procedures that involve muscle relaxation.
• Situations where combined anticholinergic and cholinesterase‑inhibiting effects are clinically advantageous.
• Supportive care in patients with certain types of postoperative respiratory compromise.

Side‑effect profiles for Glycostigmin reflect the pharmacology of both glycopyrronium bromide and neostigmine methylsulfate. Reported events vary in frequency and severity.

Common

• Dry mouth or reduced salivation.
• Mild tachycardia.
• Transient facial flushing.
• Nausea or mild gastrointestinal upset.
• Light‑headedness or dizziness.

Serious

• Severe bradycardia or arrhythmias.
• Bronchospasm or respiratory distress.
• Marked hypotension.
• Acute cholinergic crisis with muscle fasciculations.
• Allergic reactions such as urticaria or angioedema.

When using Glycostigmin, clinicians should observe several safety considerations to minimize risk. Important precautions include:

• Assess cardiac history, especially for arrhythmias, before administration.
• Monitor respiratory function closely in patients with asthma or chronic obstructive pulmonary disease.
• Use caution in individuals with glaucoma or urinary retention due to anticholinergic effects.
• Adjust dosing in patients with renal impairment, as neostigmine is renally excreted.
• Ensure adequate ventilation support is available during reversal of neuromuscular blockade.
• Review allergy history for hypersensitivity to anticholinergic or cholinesterase‑inhibiting agents.

Glycostigmin may interact with other medications that affect cholinergic or cardiac function. Interaction guidance includes:

Avoid

• Other anticholinergic drugs (e.g., atropine, scopolamine) that could potentiate dry‑mouth or tachycardia.
• Beta‑blockers or calcium‑channel blockers in patients prone to bradycardia.
• Drugs that prolong the QT interval, increasing arrhythmia risk.

Use with caution

• Neuromuscular blocking agents; timing of reversal should be carefully coordinated.
• Opioids, as combined respiratory depressant effects may occur.
• Diuretics, which can alter electrolyte balance and affect neuromuscular transmission.
• Antihistamines, which may enhance anticholinergic side effects.